ok thanks...
>Do you think that a few FDA docs who knew about the poor preapproval inspection outcome also noted that DNDN's CEO sold $2.7 million of DNDN shares without telling his shareholders about that problem? <
It certainly wouldn't surprise me if some of the FDA insiders have enough stories to fill quite a few volumes of books. So yeah, one of the guys on the FDA manufacturing side may have curiously checked out DNDN and saw the sales and tsked... problem for the FDA people is that I would believe the punishment for their indiscretions, if they were to talk, would be much greater than the punishment that a biotech ceo... er... BOD would dish out to the ceo. Maybe they angled for the approvable to punish gold's bad behaviour? Unlikely, but a funny thought.
Around the time of gold's sale, I did speculate that something strange was afoot. Gold was the only day-to-day insider that sold (i think most bod members are arm's length and not greatly involved), and I thought it fishy that everyone else was passing up a huge payday. Either those other officers were really, really bad at selling for a 2 or 300 percent profit, or they genuinely believed it inappropriate to sell given the confidential information they possessed. If that is the case, it would indirectly reveal gold's motive in not disclosing the problem(s) that they encountered.